

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and is not intended to and does not constitute any offer or invitation to acquire, purchase or subscribe for any securities of the Company, the Offeror or any other entity, nor is it a solicitation of any vote or approval in any jurisdiction. This joint announcement is not for release, publication or distribution, in whole or in part, in any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

**CATHAY INTERNATIONAL PHARMA
MANUFACTURE AND DISTRIBUTION (CHINA) LIMITED**

*(incorporated in the British Virgin Islands with
limited liability)*



**LANSEN PHARMACEUTICAL HOLDINGS LIMITED
朗生醫藥控股有限公司**

*(incorporated in the Cayman Islands with limited liability)
(Stock code: 503)*

**JOINT ANNOUNCEMENT
DELAY IN DESPATCH OF SCHEME DOCUMENT**

Reference is made to the joint announcement issued by Lansens Pharmaceutical Holdings Limited (the “**Company**”) and Cathay International Pharma Manufacture and Distribution (China) Limited (the “**Offeror**”) dated 15 September 2023 in relation to the proposed privatisation of the Company by way of a scheme of arrangement under section 86 of the Companies Act (the “**Joint Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Joint Announcement.

Pursuant to Rule 8.2 of the Takeovers Code, unless the Executive’s consent is obtained, the Scheme Document including, among other things, further details of the Proposal and the Scheme, an explanatory memorandum as required under the rules of the Grand Court, the expected timetable relating to the Proposal, the recommendations of the Independent Board Committee, the letter of advice from the Independent Financial Adviser and notices of the Court Meeting and the General Meeting should be despatched to the Shareholders within 21 days of the date of the Joint Announcement, which in this case would be on or before 6 October 2023.

The despatch of the Scheme Document and certain key dates of the proposed privatisation of the Company (including the date of the Court Meeting) are subject to the Grand Court issuing its directions for convening the Court Meeting. The Company proposes to seek a directions hearing date of 27 October 2023 (the “**Hearing**”), and the Scheme Document would be despatched as soon as practicable thereafter and estimated to be no later than 3 November 2023.

The abovementioned time and date for the Hearing is indicative only and is subject to change. A detailed expected timetable for the implementation of the Proposal will be set out in the Scheme Document and in the joint announcement to be jointly made by the Company and the Offeror upon the despatch of the Scheme Document.

Based on the above reasons, an application was made to the Executive and the Executive has indicated that it is minded to grant its consent to extend the date of despatch of the Scheme Document to a date no later than 3 November 2023. Further announcement(s) will be made by the Company and the Offeror as and when appropriate in compliance with the Takeovers Code.

WARNING

Shareholders and/or potential investors should be aware that the implementation of the Proposal and the Scheme is subject to the Conditions being fulfilled or waived, as applicable, and therefore the Proposal may or may not be implemented and the Scheme may or may not become effective. Shareholders and/or potential investors should therefore exercise caution when dealing in securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

By order of the board of directors of
**Cathay International Pharma Manufacture And
Distribution (China) Limited**
Siu Ka Chi Eric
Director

By order of the board of directors of
Lansen Pharmaceutical Holdings Limited
Chen Li
Executive Director

Hong Kong, 6 October 2023

As at the date of this joint announcement, the Board comprises Mr. Chen Li being the executive managing Director, Mr. Wu Zhen Tao and Ms. Liu Xuezi being the non-executive Directors, and Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen, Ms. Chan Ching Har, Eliza and Dr. Zhu Xun being the independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror and Offeror Concert Parties) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the directors of the Offeror and Mr. Wu Zhen Tao in their capacity as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the directors of the Offeror are Mr. Siu Ka Chi Eric and Mr. Patrick Sung. The ultimate beneficial owner of the Offeror is First Lucky Star Trust, the settlor of which is Mr. Wu Zhen Tao, and the beneficiaries include Mr. Wu Zhen Tao and his family members.

The directors of the Offeror and Mr. Wu Zhen Tao jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Company) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Directors in their capacity as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.